Search

Displaying results 5811 - 5820 of 7604 in total
  1. Drug

    Rokitamycin

    go.drugbank.com/drugs/DB13409
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Niperotidine

    go.drugbank.com/drugs/DB13760
    Investigational

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  3. Drug

    Alternaria alternata

    go.drugbank.com/drugs/DB10424
    Approved

    Alternaria alternata is a fungus which can provoke allergic reactions. Alternaria alternata extract is used in allergenic testing.

    Mixtures: Number Four Mold Mixture
  4. Drug

    Velafermin

    go.drugbank.com/drugs/DB06493
    Investigational

    Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract.

  5. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  6. Drug

    Tioxolone

    go.drugbank.com/drugs/DB13343
    Experimental

    Categories: Anti-Acne Preparations for Topical Use
  7. Drug

    Eprozinol

    go.drugbank.com/drugs/DB13395
    Experimental

    Categories: Drugs for Obstructive Airway Diseases
  8. Drug

    Mepartricin

    go.drugbank.com/drugs/DB13633
    Investigational

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  9. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

  10. Drug

    OXI-4503

    go.drugbank.com/drugs/DB05143
    Investigational

    OXI-4503 is investigated in clinical trials for treating cancer/tumors. OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. … Preclinical studies have demonstrated that OXI-4503 has (i) single-agent activity against a range of xenograft tumor models; and (ii) synergistic or additive effects when incorporated in various combination